Navigation Links
PhRMA and Epilepsy Foundation Report More Than 400 Medicines in Development to Treat Neurological Disorders
Date:7/13/2015

WASHINGTON, July 13, 2015 /PRNewswire-USNewswire/ -- America's biopharmaceutical research companies are currently developing 420 medicines for patients suffering from neurological disorders, including epilepsy, Alzheimer's disease, multiple sclerosis (MS) and Parkinson's disease. As highlighted in a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Epilepsy Foundation, scientists around the globe are collaborating to find new or more effective treatments for patients with these complex disorders that attack the nervous system.

"Researchers have made tremendous advances in understanding how the nervous system works at the molecular and genetic levels which in turn has translated into the development of more effective treatments for neurological disorders," said John J. Castellani, president and chief executive officer, PhRMA. "These developments mean new options and new hope for the millions of patients suffering from these devastating disorders. As an industry, we remain steadfast in our efforts to unlock the mysteries of these diseases and reduce their burden for generations to come."

Medicines in Development for Neurological Disorders
Medicines in Development for Neurological Disorders
Need for New Treatments for Alzheimer's Disease
Need for New Treatments for Alzheimer's Disease

Neurological disorders consist of more than 600 conditions, impacting an estimated 50 million Americans every year. Although some are well known, many are rare disorders that affect a small number of patients who currently have access to few – if any – effective treatments.

The new report, "Medicines in Development for Neurological Disorders," demonstrates how the newest advancements seek to treat the underlying mechanisms of neurological disorders. Examples of treatments currently in development include:

  • A monoclonal antibody that inhibits the activity of calcitonin gene-related peptide (CGRP). Research suggests that CGRP pathways may be involved in the development of migraines and by inhibiting CGRP activity, anti-CGRP antibodies help inhibit the transmission of pain signals associated with migraines.
  • A medicine for Huntington's disease that targets an enzyme, PDE10A, which is present in the neurons most damaged in this inherited disorder that causes a progressive breakdown of nerve cells in the brain.
  • A monoclonal antibody for amyotrophic lateral sclerosis (ALS), which is an inhibitor of the protein Nogo-A that may help keep the motor neurons and muscle fibers connected in hopes that it will lead to a slowing or stopping of disease progression.
  • A monoclonal antibody for relapsing MS, which targets a protein involved in the development of myelin, a protective sheath covering the nerve fibers. This medicine could help restore nerve communication in MS patients.

"As a parent of a child living with epilepsy, I know just how important innovation is to improving the quality of life for individuals living with seizures," said Philip M. Gattone, president and CEO of the Epilepsy Foundation. "Innovative new therapies are particularly important for the one-third of people with epilepsy who don't have their seizures under control, as well as the millions of other Americans living with chronic conditions that cannot be managed by current treatment options."

With 420 medicines in human clinical trials or under review by the Food and Drug Administration (FDA), these new treatments represent a growing understanding of neurological disorders, fueled by both successes and setbacks in research, which will ultimately provide patients and their families with better options.

About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $51.2 billion in 2014 alone.

Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.FromHopetoCures.org
www.Facebook.com/PhRMA
www.Twitter.com/PhRMA

About the Epilepsy Foundation
The Epilepsy Foundation, a national non-profit with nearly 50 affiliated organizations throughout the United States, has led the fight against seizures since 1968. The Foundation is an unwavering ally for individuals and families impacted by epilepsy and seizures. The mission of the Epilepsy Foundation is to stop seizures and SUDEP, find a cure, and overcome the challenges created by epilepsy through efforts including education, advocacy, and research to accelerate ideas into therapies. The Foundation works to ensure that people with seizures have the opportunity to live their lives to their fullest potential. For additional information, please visit www.epilepsy.com.

"Like" the Epilepsy Foundation on Facebook at www.Facebook.com/epilepsyfoundationofamerica and follow us on Twitter at www.twitter.com/epilepsyfdn.

Photo - http://photos.prnewswire.com/prnh/20150713/235611-INFO 
Photo - http://photos.prnewswire.com/prnh/20150713/235612-INFO
Logo - http://photos.prnewswire.com/prnh/20091027/PHRMALOGO


 


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. PhRMA Launches "Im Not Average" Campaign to Highlight the Stories of Cancer Survivors
2. PhRMA Foundation Launches New Web Platform to Support Researchers in Developing Life-Saving, Cost-Effective Medicines
3. Week in Review: The Latest from PhRMA
4. PhRMA Foundation Announces New Young Investigator Grantees to Advance Medication Adherence Research
5. Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman
6. PhRMA Applauds 2015 We Work For Health Champion Award Winners
7. PhRMA Member Companies Invested $51.2 Billion in R&D in 2014
8. National Minority Quality Forum to Award PhRMA President John Castellani for Leadership in Increasing Clinical Trial Diversity
9. PhRMA Elects New Members of Board of Directors
10. UCB and IBM Collaborate to Personalize Care for Epilepsy Patients
11. Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2017)... FLINT, Mich. , July 31, 2017  Diplomat Pharmacy, ... companies in southeast Michigan by ... feature ranks private and public companies by three-year revenue growth. ... To view the complete list, ... Crain,s Fast 50 is an incredible triumph," said Phil ...
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... July 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... for the second-quarter 2017 and updated financial guidance for ... Second-Quarter 2017 Highlights Reported net sales ... the prior-year quarter. Net sales at constant currency (organic) ... EPS was $0.51, compared to $0.60 in the prior-year ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... Brookfield, WI-based RF ... hospitality and education, is celebrating its 30th year in business this month. , ... manufacturing companies Square D, Allis Chalmers and Johnson Controls. Following his years in ...
(Date:8/17/2017)... ... August 17, 2017 , ... Recently ... once more by being among Houston’s first plastic surgeons to offer boutique and ... surgery care without disrupting busy schedules and maintaining the utmost discretion in the ...
(Date:8/17/2017)... Angeles, CA (PRWEB) , ... August 17, 2017 , ... ... partners Mark Hardiman, John Mills and Harry Nelson. This is the third consecutive year ... for Nelson. Hardiman and Nelson were both recognized for expertise in Health Care Law ...
(Date:8/17/2017)... ... August 17, 2017 , ... Tanya Atagi, MD, is excited ... CO, at Atagi Plastic Surgery and Skin Aesthetics. , To tighten skin on ... radiofrequency and ultrasound energy. Smoother, younger-looking skin is revealed on all other areas of ...
(Date:8/17/2017)... ... 17, 2017 , ... Dr. Charles W. Grimsley’s new book ... paperback, 9781498497626; $7.99, eBook, 9781498497633) focuses on the treatment of veterans diagnosed with ... forgiveness, through a progressive journey toward healing. This book will help readers learn ...
Breaking Medicine News(10 mins):